Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020” clinical trials has been added to ResearchAndMarkets.com’s offering.

“Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020” provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario.

This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Key Topics Covered:

Report Guidance

• Clinical Trials Report Coverage

Clinical Trials by Region

• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

• In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

• Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

• Prominent Sponsors
• Top Companies Participating in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials

Prominent Drugs

• Clinical Trial Profile Snapshots

Appendix

Companies Mentioned

• Pfizer Inc
• Gilead Sciences Inc
• Novartis AG
• Bristol-Myers Squibb Co
• Laboratory Corp of America Holdings
• Galmed International Ltd
• Intercept Pharmaceuticals Inc
• Enanta Pharmaceuticals Inc
• Genfit SA
• Histogen Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/xdcrdp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900